Toshimitsu Uenaka

2.9k total citations
33 papers, 1.8k citations indexed

About

Toshimitsu Uenaka is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Toshimitsu Uenaka has authored 33 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 18 papers in Molecular Biology and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Toshimitsu Uenaka's work include HER2/EGFR in Cancer Research (9 papers), Cancer Treatment and Pharmacology (7 papers) and Cancer therapeutics and mechanisms (6 papers). Toshimitsu Uenaka is often cited by papers focused on HER2/EGFR in Cancer Research (9 papers), Cancer Treatment and Pharmacology (7 papers) and Cancer therapeutics and mechanisms (6 papers). Toshimitsu Uenaka collaborates with scholars based in Japan, United States and Switzerland. Toshimitsu Uenaka's co-authors include Makoto Asada, Akihiko Tsuruoka, Yasuhiro Funahashi, Junji Matsui, Tatsuo Watanabe, Toshiaki WAKABAYASHI, Tatsuo Watanabe, Yuji Yamamoto, Seiji Yano and Tadaaki Yamada and has published in prestigious journals such as SHILAP Revista de lepidopterología, Cancer Research and Clinical Cancer Research.

In The Last Decade

Toshimitsu Uenaka

32 papers receiving 1.8k citations

Peers

Toshimitsu Uenaka
Akihiko Tsuruoka Japan
Stefan Engst United States
Yongchang Shi United States
Fawn Qian United States
Jessica Orf United States
Dana T. Aftab United States
Heike Richly Germany
Masao Iwata Japan
Randall Schreck United States
Yu-Chien Chou United States
Akihiko Tsuruoka Japan
Toshimitsu Uenaka
Citations per year, relative to Toshimitsu Uenaka Toshimitsu Uenaka (= 1×) peers Akihiko Tsuruoka

Countries citing papers authored by Toshimitsu Uenaka

Since Specialization
Citations

This map shows the geographic impact of Toshimitsu Uenaka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Toshimitsu Uenaka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Toshimitsu Uenaka more than expected).

Fields of papers citing papers by Toshimitsu Uenaka

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Toshimitsu Uenaka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Toshimitsu Uenaka. The network helps show where Toshimitsu Uenaka may publish in the future.

Co-authorship network of co-authors of Toshimitsu Uenaka

This figure shows the co-authorship network connecting the top 25 collaborators of Toshimitsu Uenaka. A scholar is included among the top collaborators of Toshimitsu Uenaka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Toshimitsu Uenaka. Toshimitsu Uenaka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Kuboki, Yasutoshi, et al.. (2024). Potential Mechanisms of Interstitial Lung Disease Induced by Antibody–Drug Conjugates Based on Quantitative Analysis of Drug Distribution. Molecular Cancer Therapeutics. 24(2). 242–250. 2 indexed citations
3.
4.
Albone, Earl F., Xiaofei Cheng, Sandun Fernando, et al.. (2020). 579P MORAb-109: A site-specific eribulin-conjugated ADC targeting human mesothelin. Annals of Oncology. 31. S491–S492. 1 indexed citations
5.
Cheng, Xin, Jing Li, Keigo Tanaka, et al.. (2018). MORAb-202, an Antibody–Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity. Molecular Cancer Therapeutics. 17(12). 2665–2675. 75 indexed citations
6.
Asano, Makoto, Junji Matsui, Murray J. Towle, et al.. (2018). Broad-spectrum Preclinical Antitumor Activity of Eribulin (Halaven®): Combination with Anticancer Agents of Differing Mechanisms. Anticancer Research. 38(6). 3375–3385. 27 indexed citations
7.
Rybinski, Katherine A., Xin Cheng, Earl F. Albone, et al.. (2018). Abstract B115: MORAb-202: a folate receptor alpha (FRA)-targeting antibody-drug conjugate, exhibiting targeted antitumor activity and bystander elimination of cancer-associated fibroblasts. Molecular Cancer Therapeutics. 17(1_Supplement). B115–B115. 1 indexed citations
8.
Huang, Kuan‐Chun, Zhihong Chen, Yimin Jiang, et al.. (2016). Apratoxin A Shows Novel Pancreas-Targeting Activity through the Binding of Sec 61. Molecular Cancer Therapeutics. 15(6). 1208–1216. 55 indexed citations
9.
Nakagawa, Takayuki, Shinji Takeuchi, Tadaaki Yamada, et al.. (2012). Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR -Mutant Lung Cancer. Molecular Cancer Therapeutics. 11(10). 2149–2157. 74 indexed citations
10.
Wang, Wei, Qi Li, Shinji Takeuchi, et al.. (2012). Met Kinase Inhibitor E7050 Reverses Three Different Mechanisms of Hepatocyte Growth Factor–Induced Tyrosine Kinase Inhibitor Resistance in EGFR Mutant Lung Cancer. Clinical Cancer Research. 18(6). 1663–1671. 76 indexed citations
11.
Yamada, Tadaaki, Shinji Takeuchi, Junya Nakade, et al.. (2012). Paracrine Receptor Activation by Microenvironment Triggers Bypass Survival Signals and ALK Inhibitor Resistance in EML4-ALK Lung Cancer Cells. Clinical Cancer Research. 18(13). 3592–3602. 93 indexed citations
12.
Ogino, Hirokazu, Masaki Hanibuchi, Soji Kakiuchi, et al.. (2011). E7080 Suppresses Hematogenous Multiple Organ Metastases of Lung Cancer Cells with Nonmutated Epidermal Growth Factor Receptor. Molecular Cancer Therapeutics. 10(7). 1218–1228. 16 indexed citations
13.
Iwata, Masao, Toshimitsu Uenaka, Yoichi Ozawa, et al.. (2007). E7107: Antitumor activity on human SCLC and cervical cancer xenografts in relation to its potential predictive markers of response.. Cancer Research. 67. 5608–5608. 1 indexed citations
14.
Matsui, Junji, Yuji Yamamoto, Yasuhiro Funahashi, et al.. (2007). E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. International Journal of Cancer. 122(3). 664–671. 434 indexed citations
15.
Niijima, Jun, Yoshihiko Kotake, Mitsuo Nagai, et al.. (2004). E7107, a new 7-urethane derivative of pladienolide D: Discovery of a novel antitumor agent. Cancer Research. 64. 691–691. 18 indexed citations
16.
Mizui, Yoshiharu, Takashi Sakai, Masao Iwata, et al.. (2004). Pladienolides, New Substances from Culture of Streptomyces platensis Mer-11107 III. In Vitro and In Vivo Antitumor Activities. The Journal of Antibiotics. 57(3). 188–196. 163 indexed citations
17.
Nakamura, Katsuji, Toshimitsu Uenaka, Takeshi Nagasu, et al.. (2003). A novel carbazole topoisomerase II poison, ER‐37328: potent tumoricidal activity against human solid tumors in vitro and in vivo. Cancer Science. 94(1). 119–124. 15 indexed citations
18.
Nakamura, Katsuji, Hiroyuki Sugumi, Atsumi Yamaguchi, et al.. (2002). Antitumor activity of ER-37328, a novel carbazole topoisomerase II inhibitor.. PubMed. 1(3). 169–75. 21 indexed citations
19.
Dohmae, Naoshi, Koji Takio, Toshimitsu Uenaka, et al.. (1999). A Monoclonal Antibody, 3A10, Recognizes a Specific Amino Acid Sequence Present on a Series of Developmentally Expressed Brain Proteins. The Journal of Biochemistry. 125(3). 443–448. 11 indexed citations
20.
Aoki, Yoshiko, Toshimitsu Uenaka, Junken Aoki, Masato Umeda, & Keizo Inoue. (1994). A Novel Peptide Probe for Studying the Transbilayer Movement of Phosphatidylethanolamine. The Journal of Biochemistry. 116(2). 291–297. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Akihiko Tsuruoka Breakdown of academic impact, for papers by Stefan Engst Breakdown of academic impact, for papers by Yongchang Shi Breakdown of academic impact, for papers by Fawn Qian Breakdown of academic impact, for papers by Jessica Orf Breakdown of academic impact, for papers by Dana T. Aftab Breakdown of academic impact, for papers by Heike Richly Breakdown of academic impact, for papers by Masao Iwata Breakdown of academic impact, for papers by Randall Schreck Breakdown of academic impact, for papers by Yu-Chien Chou
Rankless by CCL
2026